Central Pharmaceutical Joint Stock Company No3: Q3 2024 delivered higher profit and margin, but nine-month results reflect ongoing market headwinds

Q3 2024 saw revenue and net profit growth year-over-year, with improved gross margin and strong liquidity, though nine-month revenue and profit declined slightly due to market pressures.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.